Skip to search formSkip to main contentSkip to account menu

verubecestat

Known as: N-(3-(3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
BACKGROUND Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid… 
2019
2019
β‐site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of β‐amyloid (Aβ) peptides and is… 
2019
2019
  • S. Doggrell
  • Expert opinion on pharmacotherapy
  • 2019
  • Corpus ID: 201063555
ABSTRACT Introduction: The amyloid-beta (Aβ) cascade hypothesis is that reducing Aβ levels in the brain will be beneficial in… 
Highly Cited
2018
Highly Cited
2018
BACKGROUND Alzheimer's disease is characterized by the deposition of amyloid‐beta (Aβ) plaques in the brain. Aβ is produced from… 
2018
2018
The development of a commercial manufacturing route to verubecestat (MK-8931) is described, highlights of which include the… 
2017
2017
Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to… 
Highly Cited
2016
Highly Cited
2016
The BACE1 inhibitor verubecestat safely reduces β-amyloid deposition in rats, monkeys, healthy human subjects, and patients with… 
Highly Cited
2016
Highly Cited
2016
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity… 
2016
2016
Verubecestat is an inhibitor of β-secretase being evaluated for the treatment of Alzheimer's disease. The first-generation route…